Business Wire



TransEnterix Announces First Radical Hysterectomy Performed with Senhance™ Surgical Robot

TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that the first radical hysterectomy for cervical cancer utilizing its Senhance surgical robot was performed by gynecologic surgeon Dr. Salvatore Gueli Alletti, a member of Professor Giovanni Scambia’s team, at the Policlinico A. Gemelli Foundation in Rome, Italy.

“This is an exciting development in the minimally invasive surgical field. The Senhance system was successfully utilized to perform a radical hysterectomy with bilateral pelvic lymphadenectomy,” said Dr. Gueli Alletti. ”This is an extensive oncological dissection, and the system’s precision, camera control, ergonomics and haptics were important benefits to help perform this operation safely and effectively. I strongly believe that the Senhance is a promising technology in complex gynecologic oncology.”

A radical hysterectomy is performed for early stage cervical cancer and involves the dissection and removal of all the uterus and parametria, ovaries, fallopian tubes and the upper portion of the vagina. The operation is a major cancer operation which includes an extensive pelvic lymph node dissection.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at .

Forward Looking Statements

This press release includes statements relating to The Senhance™ Surgical Robotic System and the SurgiBot™ System and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether the Senhance system is a promising technology in complex gynecologic oncology. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1 443-213-0501
Media Contact:
(For EU) Conrad Harrington, +44 (0)20 3178 8914
(For US) Hannah Dunning, +1 415-618-8750



Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco